Zhejiang Chimin Pharm Co Ltd
Chimin Health Management Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells vitro diagnostic products and provides medical services in China and internationally. The company provides non-PVC double-tube double-valve, single-tube single-valve, and single-tube double-valve soft bags; plastic bottles; and other packaging forms. It also offers medical instruments, in… Read more
Zhejiang Chimin Pharm Co Ltd (603222) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.01 Billion CNY
Based on the latest financial reports, Zhejiang Chimin Pharm Co Ltd (603222) has total liabilities worth CN¥1.01 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Chimin Pharm Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Zhejiang Chimin Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang Chimin Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Chimin Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Yongli Belting Co Ltd
SHE:300230
|
China | CN¥952.58 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$44.15 Million |
|
Douglas AG
XETRA:DOU
|
Germany | €4.13 Billion |
|
Zhejiang Tengen Electrics Co Ltd
SHG:605066
|
China | CN¥1.35 Billion |
|
Agora Inc
NASDAQ:API
|
USA | $158.25 Million |
|
Marcus Corporation
NYSE:MCS
|
USA | $549.96 Million |
|
SK Networks Co Ltd
KO:001740
|
Korea | ₩3.22 Trillion |
|
OPUS GLOBAL Nyrt
BUD:OPUS
|
Hungary | Ft602.11 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Zhejiang Chimin Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Chimin Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Chimin Pharm Co Ltd (2011–2024)
The table below shows the annual total liabilities of Zhejiang Chimin Pharm Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥846.22 Million | +3.18% |
| 2023-12-31 | CN¥820.13 Million | -12.72% |
| 2022-12-31 | CN¥939.64 Million | -10.55% |
| 2021-12-31 | CN¥1.05 Billion | -15.67% |
| 2020-12-31 | CN¥1.25 Billion | +23.13% |
| 2019-12-31 | CN¥1.01 Billion | -6.17% |
| 2018-12-31 | CN¥1.08 Billion | +66.75% |
| 2017-12-31 | CN¥646.63 Million | +469.79% |
| 2016-12-31 | CN¥113.49 Million | +22.00% |
| 2015-12-31 | CN¥93.02 Million | -50.65% |
| 2014-12-31 | CN¥188.49 Million | -16.32% |
| 2013-12-31 | CN¥225.24 Million | -12.73% |
| 2012-12-31 | CN¥258.10 Million | -5.20% |
| 2011-12-31 | CN¥272.26 Million | -- |